Medical Department, Chiesi Farmaceutici, Parma, Italy.
Ital J Pediatr. 2011 Aug 22;37:39. doi: 10.1186/1824-7288-37-39.
Few data are available on the usefulness of short term treatment with low-medium dose of inhaled corticosteroids (ICS) in pre-school children with wheezing exacerbations.
To compare the efficacy of one week treatment with 400 μg b.i.d. nebulized beclomethasone dipropionate (BDP), plus nebulized 2500 μg prn salbutamol (BDP group), versus nebulized b.i.d. placebo, plus nebulized prn 2500 μg salbutamol (placebo group), a post-hoc analysis was performed on data obtained in 166 pre-school children with multiple-trigger wheezing, recruited during an acute wheezing episode.
The percentage of symptom-free days (SFDs) was significantly higher in the BDP group (54.7%) than in the placebo group (40.5%; p = 0.012), with a 35% relative difference. Day-by-day analysis showed that the percentage of SFDs was already higher in the BDP group after 2 days (7.4%), the difference reaching statistical significance at day 6 (12.3%; p = 0.035). Cough score was also reduced in the BDP group (0.11) as compared with the placebo group (0.39; p = 0.048), the difference reaching statistical significance after 5 days of treatment (0.18 and 0.47 respectively; p = 0.047). The mean number of nebulizations per day of prn salbutamol was lower in the BDP group as compared to the placebo group (0.26 and 0.34, respectively), but the difference was not significant (p = 0.366). There were no differences in positive effects of BDP treatment between children with and without risk factors for asthma.
A 1-week treatment with nebulized BDP and prn salbutamol is effective in increasing SFDs and improving cough in children with wheezing, providing a clinical rationale for the short term use of ICS in episodic wheeze exacerbations in pre-school children.
关于在有喘息加重的学龄前儿童中短期使用低至中剂量吸入性皮质类固醇(ICS)的有效性,相关数据较少。
为了比较为期一周的治疗方案的效果,该方案使用的药物是 400μg 沙丁胺醇雾化吸入(b.i.d.)布地奈德丙酸酯(BDP),联合按需使用 2500μg 沙丁胺醇雾化吸入(BDP 组),或使用 b.i.d.安慰剂,联合按需使用 2500μg 沙丁胺醇雾化吸入(安慰剂组)。在 166 例因多重触发喘息而就诊的学龄前儿童中,对其急性喘息发作期间获得的数据进行了事后分析。
BDP 组(54.7%)无症状天数(SFDs)的百分比明显高于安慰剂组(40.5%;p=0.012),相对差异为 35%。逐天分析显示,BDP 组在治疗的第 2 天(7.4%)无症状天数百分比就更高,在第 6 天(12.3%)差异有统计学意义(p=0.035)。BDP 组的咳嗽评分(0.11)也低于安慰剂组(0.39;p=0.048),治疗 5 天后差异有统计学意义(分别为 0.18 和 0.47;p=0.047)。BDP 组按需使用沙丁胺醇雾化吸入的平均次数少于安慰剂组(分别为 0.26 和 0.34),但差异无统计学意义(p=0.366)。BDP 治疗的积极效果在有和没有哮喘危险因素的儿童之间没有差异。
在有喘息的儿童中,为期一周的布地奈德丙酸酯和沙丁胺醇按需治疗可增加无症状天数和改善咳嗽,为学龄前儿童中短期使用 ICS 治疗间歇性喘息加重提供了临床依据。